ArticleBMC research notes2026
Stage-wise variation in serum C-reactive protein and cardiovascular risk in chronic kidney disease of uncertain etiology among Sri Lankans; a preliminary study.
Article in BMC research notes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundChronic kidney disease of uncertain etiology (CKDu) is a progressive nephropathy histologically characterized by tubulointerstitial fibrosis with varying degrees of inflammatory infiltrations. C-reactive protein (CRP) is an acute phase protein that serves as a marker of systemic inflammation and cardiovascular disease (CVD) risk. Therefore, this study aimed to evaluate serum CRP levels in patients with CKDu and to assess their association with renal function and CVD risk.
methodsA cross-sectional study was conducted on 40 clinically diagnosed CKDu patients at different severity stages (stage 2 (n = 5, 12.5%), stage 3A (n = 8, 20.0%), stage 3B (n = 10, 25.0%), stage 4 (n = 10, 25.0%), and stage 5 (n = 7, 17.5%). As the control group, age and sex matched 16 apparently healthy individuals (mean age 52.19 ± 10.26 years, 56.2% male) were recruited. CRP concentrations were measured using immunoturbidimetry (range 0-150 mg/L), and CVD risk was categorized based on CDC/AHA guideline. Patients with CRP > 10 mg/L were excluded to minimize confounding from potential underlying infections.
resultsCRP levels across CKDu stages demonstrated a nonlinear trend with significant peak at stage 3A (1.6 mg/L; IQR: 1.08-2.95), compared to their matched control subjects (0.50 mg/L; IQR 0.30-1.73; p = 0.0045), followed by a decline in later stages. No significant association was observed between CRP and eGFR (r = 0.11, 95% CI -0.21 to 0.41, p = 0.49). After classifying the CKDu patients for CVD risk, Stage 3A patients had higher odds of increased CVD risk than controls (odds ratio = 21.0, p = 0.0236) followed by stage 3B (odds ratio = 13.5, p = 0.0352). Further, CVD risk stratification was not confounded by age, sex, and renal function indicators (eGFR and serum creatinine).
conclusionElevated CRP levels and associated CVD risk in CKDu patients appear most pronounced in intermediate disease stages (3A-3B), providing a rationale for a large longitudinal study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.